世界のがん遺伝子治療市場2022-2030:治療別(腫瘍溶解性ウイルス療法、遺伝子誘導免疫療法、遺伝子導入法)、最終用途別、地域別

【英語タイトル】Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), By End-use, By Region, And Segment Forecasts, 2022 - 2030

Grand View Researchが出版した調査資料(GRV22NV018)・商品コード:GRV22NV018
・発行会社(調査会社):Grand View Research
・発行日:2022年10月7日
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,324,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社は、世界のがん遺伝子治療市場規模が、2022年から2030年の間に年平均19.99%成長し、2030年までに87億ドルに達すると予測しています。当調査レポートでは、がん遺伝子治療の世界市場について総合的に調査・分析を行い、調査手法・範囲、エグゼクティブサマリー、産業見通し、競争状況、治療別(腫瘍溶解性ウイルス療法、遺伝子誘導免疫療法、遺伝子導入法)分析、最終用途別(研究機関、バイオ医薬品企業、診断センター、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、企業情報などの構成でまとめています。なお、当書に掲載されている企業情報には、Abeona Therapeutics Inc.、Asklepios BioPharmaceutical Inc.、Celgene(Bristol-Myers Squibb Company)、Elevate Bio、GlaxoSmithKline Inc.、Bluebird bio Inc.、Genelux Corporation、OncoGenex Pharmaceuticals Inc.、Introgen Therapeutics Inc.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・産業見通し
・競争状況
・世界のがん遺伝子治療市場規模:治療別
- 腫瘍溶解性ウイルス療法の市場規模
- 遺伝子誘導免疫療法の市場規模
- 遺伝子導入法の市場規模
・世界のがん遺伝子治療市場規模:最終用途別
- 研究機関における市場規模
- バイオ医薬品企業における市場規模
- 診断センターにおける市場規模
- その他最終用途における市場規模
・世界のがん遺伝子治療市場規模:地域別
- 北米のがん遺伝子治療市場規模
- ヨーロッパのがん遺伝子治療市場規模
- アジア太平洋のがん遺伝子治療市場規模
- 中南米のがん遺伝子治療市場規模
- 中東・アフリカのがん遺伝子治療市場規模
・企業情報

Cancer Gene Therapy Market Growth & Trends

The global cancer gene therapy market size is expected to reach USD 8.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.99% from 2022 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite’s Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights

• The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine

• The gene induced immunotherapy segment held the largest share in 2021 due to increase in the advancement in gene induced immunotherapy research

• Biopharmaceutical companies held the largest market share in 2021 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field

• North America dominated the market in 2021 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Cancer Gene Therapy Market: Methodology And Scope
1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: CAGR Calculation
1.8 Regional Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
1.11 List of Abbreviations
Chapter 2 Cancer Gene Therapy Market: Executive Summary
2.1 Cancer Gene Therapy Market: Market Outlook
2.1.1 Market Summary
Chapter 3 Cancer Gene Therapy Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 High growth of the pharmaceutical industry
3.3.1.2 Rising R&D investements and demand for novel cancer therapeutics
3.3.1.3 Increased incidence of cancers
3.3.1.4 Technological advancements
3.3.2 Market Restraint Analysis
3.3.2.1 High product prices
3.3.2.2 Unethical use of gene therapy
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis – Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Cancer Gene Therapy Market: Competitive Landscape
4.1 Recent Developments & Impact Analysis, By Key Market Participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2021
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Cancer Gene Therapy Market: Therapy Analysis
5.1 Cancer Gene Therapy Market: Therapy Movement Analysis
5.2 Oncolytic Virotherapy
5.2.1 Oncolytic virotherapy market estimates and forecast, 2018 – 2030 (USD Million)
5.3 Gene Induced Immunotherapy
5.3.1 Gene induced immunotherapy market estimates and forecast, 2018 – 2030 (USD Million)
5.4 Gene Transfer
5.3.1 Gene transfer market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 6 Cancer Gene Therapy Market: End-Use Analysis
6.1 Cancer Gene Therapy Market: End-Use Movement Analysis
6.2 Research Institutes
6.2.1 Research institutes based cancer gene therapy market estimates and forecast, 2018 – 2030 (USD Million)
6.3 Biopharmaceutical Companies
6.3.1 Biopharmaceutical companies based cancer gene therapy market estimates and forecast, 2018 – 2030 (USD Million)
6.4 Diagnostic Centres
6.4.1 Diagnostic centres based cancer gene therapy market estimates and forecast, 2018 – 2030 (USD Million)
6.5 Other End-use
6.5.1 Other end-use based cancer gene therapy market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 7 Cancer Gene Therapy Market: Regional Business Analysis
7.1 Market Share Analysis by Country, 2021 & 2030
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2018 – 2030 (USD Million)
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2018 – 2030 (USD Million)
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.2 U.K.
7.1.2.2.1 U.K. market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.5 Italy
7.1.2.5.1 Italy market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.6 Spain
7.1.2.6.1 Spain market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.5 South Korea
7.1.3.5.1 South Korea market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.6 Australia
7.1.3.6.1 Australia market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.3 Mexico
7.1.4.3.1 Mexico market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.4 Argentina
7.1.4.4.1 Argentina market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5 Middle East And Africa
7.1.5.1 Middle East & Africa market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.2 South Africa
7.1.5.2.1 South Africa market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.3 Saudi Arabia
7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.4 UAE
7.1.5.4.1 UAE market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 8 Cancer Gene Therapy Market: Company Profiling
8.1 Company Profiles
8.1.1 Abeona Therapeutics Inc.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 Asklepios BioPharmaceutical Inc.
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Celgene(Bristol-Myers Squibb Company)
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Elevate Bio
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 GlaxoSmithKline Inc.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Bluebird bio Inc.
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7 Genelux Corporation
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 OncoGenex Pharmaceuticals Inc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Introgen Therapeutics Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Altor Bioscience Inc.
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
8.1.11 Merck & Co., Inc.
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
8.1.12 GenVec
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Product benchmarking
8.1.12.4 Strategic initiatives
8.1.13 BioCancell Inc.
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Product benchmarking
8.1.13.4 Strategic initiatives
8.2 List of Other Key Players



★調査レポート[世界のがん遺伝子治療市場2022-2030:治療別(腫瘍溶解性ウイルス療法、遺伝子誘導免疫療法、遺伝子導入法)、最終用途別、地域別] (コード:GRV22NV018)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のがん遺伝子治療市場2022-2030:治療別(腫瘍溶解性ウイルス療法、遺伝子誘導免疫療法、遺伝子導入法)、最終用途別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆